Nintedanib* plus docetaxel in routine clinical practice: VARGADO ‒ a German prospective non-interventional study reflecting routine treatment conditions in an evolving NSCLC treatment landscape
Grohé C, Zander I, Lüdtke-Heckenkamp K, Blau W, Krüger S, Franke C, Müller-Huesmann H, Brückl W, Basara N, Ukena D, Lang S, Atz J, Kaiser R
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: October 2018
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue